Supplementary Appendix

 Table S1
 List of immunosuppressant and cancer treatment drugs

Drug name	ATC code					
Immunosuppressant drugs						
6-mercaptopurine	L01BB02					
Abatacept	L04AA24					
Adalimumab	L04AB04					
Alemtuzumab	L04AA34					
Anakinra	L04AC03					
Apremilast	L04AA32					
Azathioprine	L04AX01					
Baricitinib	L04AA37					
Basiliximab	L04AC02					
Belatacept	L04AA28					
Belimumab	L04AA26					
Bendamustine	L01AA09					
Brentuximab	L01FX05					
Busulfan	L01AB01					
Canakinumab	L04AC08					
Certolizumab	L04AB05					
Chlorambucil	L01AA02					
Cyclophosphamide	L01AA01					
Cyclosporine	L04AD01					
Dacarbazine	L01AX04					
Daclizumab	L04AC01					
Dimethyl fumarate	L04AX07, N07XX09					
Eculizumab	L04AA25					
Elotuzumab	L01FX08					
Estramustine	L01XX11					
Etanercept	L04AB01					
Everolimus	L04AA18, L01EG02, L01EG01					
Fingolimod	L04AA27					
Fotemustine	L01AD05					
Glatiramer acetate	L03AX13					
Golimumab	L04AB06					
Ifosfamide	L01AA06					

Infliximab	L04AB02				
Ipilimumab	L01FX04				
Ixekizumab	L04AC13				
Leflunomide	L04AA13				
Melphalan	L01AA03				
Methotrexate	L01BA01, L04AX03				
Mitoxantrone	L01DB07				
Mycophenolate mofetil	L04AA06				
Natalizumab	L04AA23				
Obinutuzumab	L01FA03				
Prednisone (≥20 mg for ≥14 days)	S01BA04, H02AB06, A07EA01, C05AA04,				
	R01AD02, S01BA03				
Rituximab	L01FA01				
Secukinumab	L04AC10				
Siltuximab	L04AC11				
Sirolimus	L04AA10, S01XA23				
Tacrolimus	L04AD02				
Temozolomide	L01AX03				
Teriflunomide	L04AA31				
Thiotepa	L01AC01				
Tocilizumab	L04AC07				
Tofacitinib	L04AA29				
Ustekinumab	L04AC05				
Vedolizumab	L04AA33				
Cancer treatment: radiotherapy drugs	,				
Radium dichloride	V10XX03				
Cancer treatment: drugs	,				
Antineoplastic agents and immunomodulating	L01				
agents					
Endocrine therapy	L02				
Immunostimulants	L03				
	•				

ATC=Anatomical Therapeutic Chemical.

Table S2 List of ICD-10 codes to identify immunocompromised patients and other comorbidities

ICD-10 codes	Description
HIV	
B20	Human immunodeficiency virus (HIV) disease
B97.35	Human immunodeficiency virus, type 2 (HIV-2)
Primary immune defic	iency (disorders involving the immune mechanism)
D50-D89	Diseases of the blood and blood-forming organs and certain
	disorders involving the immune mechanism
K50	Crohn's disease (regional enteritis)
K51.90	Ulcerative enterocolitis
K52.9	Other and unspecified non-infectious gastroenteritis and colitis
L40	Psoriasis
M06.4	Rheumatoid arthritis and other inflammatory polyarthropathies
M32.9	Systemic lupus erythematosus
Q89.0, Q89.01	Asplenia (congenital)
Transplant	
T86	Complications of transplanted organs and tissue
Z94	Transplanted organ and tissue status
Solid tumours	
C00-C14	Malignant neoplasms of lip, oral cavity and pharynx
C15-C26	Malignant neoplasms of digestive organs
C30-C39	Malignant neoplasms of respiratory and intrathoracic organs
C40-C41	Malignant neoplasms of bone and articular cartilage
C43-C44	Melanoma and other malignant neoplasms of skin
C45-C49	Malignant neoplasms of mesothelial and soft tissue
C50	Malignant neoplasms of breast
C51-C58	Malignant neoplasms of female genital organs
C60-C63	Malignant neoplasms of male genital organs
C64-C68	Malignant neoplasms of urinary tract
C69-C72	Malignant neoplasms of eye, brain and other parts of central
	nervous system
C73-C75	Malignant neoplasms of thyroid and other endocrine glands
C76-C80	Malignant neoplasms of ill-defined, other secondary and
	unspecified sites
C7A	Malignant neuroendocrine tumours
C7B	Secondary neuroendocrine tumours
D00-D09	In situ neoplasms

D49	Neoplasms of unspecified behaviour					
D37–D44	Neoplasms of uncertain behaviour					
D48	Neoplasm of uncertain behaviour of other and unspecified sites					
Haematological malignancies						
C81–C96	Malignant neoplasms of lymphoid, haematopoietic and related					
	tissue					
D45-D47	Polycythaemia vera, myelodysplastic syndromes and other					
	neoplasms of uncertain behaviour of lymphoid, haematopoietic and					
	related tissue					
Sickle cell anaemia						
D57.0	Hb-SS disease with crisis					
D57.1	Sickle cell disease without crisis					
D57.2	Sickle cell/Hb-C disease					
Major thalassaemia						
D56.0	Alpha thalassaemia					
D56.1	Beta thalassaemia					
Chronic kidney disease						
N17	Acute kidney failure					
N18.4	CKD Stage 4					
N18.5	CKD Stage 5					
N18.6	ESRD					
Z99.2	Dependence on renal dialysis					
Z49	Encounter for other dialysis					
Z49.01	Fitting and adjustment of extracorporeal dialysis catheter					
Z49.02	Peritoneal dialysis					
Z49.31	Encounter for adequacy testing for haemodialysis					
Z49.32	Encounter for adequacy testing for peritoneal haemodialysis					
Chronic liver disease						
185.10	Oesophageal varices in diseases classified elsewhere, without					
	mention of bleeding					
K72.00	Acute and subacute necrosis of liver					
K72.10	Other sequelae of chronic liver disease					
K73	Chronic hepatitis, not elsewhere classified					
K72.91	Hepatic encephalopathy					
K73.9	Hepatitis, unspecified					
K74	Fibrosis and cirrhosis of liver					
K76.6	Portal hypertension					
K76.7	Hepatorenal syndrome					
K76.81	Hepatopulmonary syndrome					

K76.89	Liver disorders
K76.9	Unspecified disorder of liver
K76.1	Chronic passive congestion of liver
R18.8	Other ascites
Type 1 or type 2 dia	betes
E08	Diabetes mellitus due to underlying condition
E09	Drug or chemical induced diabetes mellitus
E10	Type 1 diabetes mellitus
E11	Type 2 diabetes mellitus
E13	Other specified diabetes mellitus
Obesity	
E66.0	Obesity due to excess calories
E66.1	Drug-induced obesity
E66.2	Morbid (severe) obesity with alveolar hypoventilation
E66.8	Other obesity
E66.9	Obesity, unspecified
Chronic cardiovasc	ular disease
I20–I25	Ischaemic heart diseases
127.0	Primary pulmonary hypertension
127.2	Other secondary pulmonary hypertension
127.81	Cor pulmonale (chronic)
127.9	Pulmonary heart disease, unspecified
I5A	Non-ischaemic myocardial injury (nontraumatic)
I30–I52	Other forms of heart disease
Q20–Q28	Congenital malformations of the circulatory system
Chronic lung diseas	Se Control of the Con
E84.9	Cystic fibrosis, unspecified
E84.11	Meconium ileus in cystic fibrosis
126	Pulmonary embolism
E84.0	Cystic fibrosis with pulmonary manifestations
127.82	Chronic pulmonary embolism
J44.9	Chronic obstructive pulmonary disease
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J84.10	Pulmonary fibrosis, unspecified
J84.89	Other specified interstitial pulmonary diseases
J98.4	Other disorders of lung
Chronic neurologica	al disease
A81.01	Variant Creutzfeldt–Jakob disease

F01.50	Vascular dementia without behavioural disturbance
F07.0	Personality change due to known physiological condition
G10	Huntington's disease
G20	Parkinson's disease
G21	Secondary parkinsonism
G23	Other degenerative diseases of basal ganglia
G24	Dystonia
G25	Other extrapyramidal and movement disorders
G26	Extrapyramidal and movement disorders in diseases classified
	elsewhere
G30	Alzheimer's disease
G31	Other degenerative diseases of nervous system, not elsewhere
	classified
G32	Other degenerative disorders of nervous system in diseases
	classified elsewhere
160	Nontraumatic subarachnoid haemorrhage
161	Nontraumatic intracerebral haemorrhage
162	Other and unspecified nontraumatic intracranial haemorrhage
163	Cerebral infarction
165	Occlusion and stenosis of precerebral arteries, not resulting in
	cerebral infarction
166	Occlusion and stenosis of cerebral arteries, not resulting in cerebral
	infarction
167	Other cerebrovascular diseases
168	Cerebrovascular disorders in diseases classified elsewhere
169	Sequelae of cerebrovascular disease
R47.01	Aphasia
R40.20	Unspecified coma
Cancer treatment: radiothera	ipy or chemotherapy
Z51.0	Encounter for antineoplastic radiation therapy
Z51.1	Encounter for antineoplastic chemotherapy and immunotherapy
COVID-19-related hospitaliza	itions
B34.2	Coronavirus infection, unspecified
U07.1	COVID-19
B97.2	Coronavirus as the cause of diseases classified elsewhere
010 1 111 11 001	ID 10-coronovirus discoso 2010, ESPD-and store repol discoso

CKD=chronic kidney disease, COVID-19=coronavirus disease 2019, ESRD=end-stage renal disease, HIV=human immunodeficiency virus, ICD-10=International Classification of Disease version 10

Table S3 List of ICD-10 procedure codes

ICD-10 codes	Description					
Invasive mechanical ventilation						
0BH13EZ	Insertion of endotracheal airway into trachea, percutaneous					
OBITISEZ	approach					
ODI 14.7E.7	Insertion of endotracheal airway into trachea, via natural or artificial					
0BH17EZ	opening					
0BH18EZ	Insertion of endotracheal airway into trachea, via natural or artificial					
OBITIOEZ	opening					
0B110F4	Bypass trachea to cutaneous with tracheostomy device, open					
06110F4	approach					
0B110Z4	Bypass trachea to cutaneous, open approach					
0B113F4	Bypass trachea to cutaneous with tracheostomy device,					
0611364	percutaneous approach					
0B113Z4	Bypass trachea to cutaneous, percutaneous approach					
0B114F4	Bypass trachea to cutaneous with tracheostomy device,					
06114F4	percutaneous endoscopic approach					
0B114Z4	Bypass trachea to cutaneous, percutaneous endoscopic approach					
	Extracorporeal or systemic assistance and performance,					
5A1.935Z	physiological systems, performance, respiratory, less than					
	24 consecutive hours, ventilation, no qualifier					
	Extracorporeal or systemic assistance and performance,					
5A1.945Z	physiological systems, performance, respiratory,					
	24–96 consecutive hours, ventilation, no qualifier					
	Extracorporeal or systemic assistance and performance,					
5A1.955Z	physiological systems, performance, respiratory, greater than 96					
	consecutive hours, ventilation, no qualifier					
Non-invasive ventilation	on					
5A0.9357	Assistance with respiratory ventilation, less than 24 consecutive					
0/10.5007	hours, continuous positive airway pressure					
5A0.9358	Assistance with respiratory ventilation, less than 24 consecutive					
0/10.0000	hours, intermittent positive airway pressure					
5A0.9359	Assistance with respiratory ventilation, less than 24 consecutive					
JAU.3333	hours, continuous negative airway pressure					
5A0.935B	Assistance with respiratory ventilation, less than 24 consecutive					
S. 10.000B	hours, intermittent negative airway pressure					
5A0.935Z	Assistance with respiratory ventilation, less than 24 consecutive					
UNU.300Z	hours					

5A0.9457	Assistance with respiratory ventilation, 24–96 consecutive hours,
5A0.9457	continuous positive airway pressure
5A0.9458	Assistance with respiratory ventilation, 24–96 consecutive hours,
	intermittent positive airway pressure
5A0.9459	Assistance with respiratory ventilation, 24–96 consecutive hours,
	continuous negative airway pressure
5A0.945B	Assistance with respiratory ventilation, 24–96 consecutive hours,
	intermittent negative airway pressure
5A0.945Z	Assistance with respiratory ventilation, 24–96 consecutive hours
5A0.9557	Assistance with respiratory ventilation, greater than 96 consecutive
	hours, continuous positive airway pressure
5A0.9558	Assistance with respiratory ventilation, greater than 96 consecutive
	hours, intermittent positive airway pressure
5A0.9559	Assistance with respiratory ventilation, greater than 96 consecutive
	hours, continuous negative airway pressure
5A0.955B	Assistance with respiratory ventilation, greater than 96 consecutive
0A0.333B	hours, intermittent negative airway pressure
5A0.955Z	Assistance with respiratory ventilation, greater than 96 consecutive
	hours
5A1.9054	Respiratory ventilation, dingle, nonmechanical
Z99.11	Dependence on respirator (ventilator) status

ICD-10=International Classification of Disease version 10

Table S4 Acute period (29-day) all-cause and COVID-19-related outcomes by study month

Outcome	Study month									
	Overall	Nov 2021	Dec 2021	Jan 2022	Feb 2022	Mar 2022	Apr 2022	May 2022	Jun 2022	Jul 2022
Number of patients treated with sotrovimab	634	20	44	178	112	148	127	1	2	2
Hospitalized due to any cause, <i>n</i> (%)	79 (12.5)	4 (20.0)	10 (22.7)	20 (11.2)	9 (8.0)	22 (14.9)	14 (11.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hospitalized due to COVID-19, <i>n</i> (%)	16 (2.5)	0 (0.0)	4 (9.1)	2 (1.1)	3 (2.7)	4 (2.7)	3 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Hospitalized due to unknown reason, <i>n</i> (%)	7 (1.1)	0 (0.0)	1 (2.3)	5 (2.8)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Died due to any cause, n (%)	7 (1.1)	0 (0.0)	1 (2.3)	2 (1.1)	2 (1.8)	2 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

COVID-19=coronavirus disease 2019